Today: 9 June 2026
Browse Category

NYSE:HIMS 3 July 2025 - 5 February 2026

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers Health shares fell 0.5% to $32.87 in premarket trading Wednesday after closing down 3.1% the previous session. The move follows price cuts by Novo Nordisk and Eli Lilly on obesity drugs in China, raising questions about future margins and demand for GLP-1 therapies. Hims recently launched its weight-loss membership in the UK, offering access to Wegovy and Mounjaro.
31 December 2025
····
Hims Stock (HIMS) Outlook for 2026: Latest News, Canada Expansion, Buyback and Price Targets as of December 6, 2025

Hims Stock (HIMS) Outlook for 2026: Latest News, Canada Expansion, Buyback and Price Targets as of December 6, 2025

Hims & Hers Health (NYSE: HIMS) closed at about $39–39.3 per share on December 5, 2025, with a market cap near $9 billion. The company authorized a new $250 million share buyback after completing its previous $100 million program. Hims reported nearly 50% year-over-year revenue growth and remains profitable. Shares have swung between $24 and $73 over the past year.
6 December 2025
·
Hims & Hers Health (HIMS) Stock Today: Canada Expansion, Labs, GLP‑1 Growth and Fresh “Strong Buy” Call – Price, News & Forecast as of December 5, 2025

Hims & Hers Health (HIMS) Stock Today: Canada Expansion, Labs, GLP‑1 Growth and Fresh “Strong Buy” Call – Price, News & Forecast as of December 5, 2025

Hims & Hers Health shares closed at $40.02 on December 4, up nearly 8%, following a Q3 revenue jump of 49% to $599 million and guidance for Q4 revenue of $605–625 million. The company announced a $250 million buyback, two acquisitions, and a new chief policy officer. Shares remain well below the 52-week high of $72.98, with short interest elevated and volatility high.
5 December 2025
··
Hims & Hers (HIMS) Stock Jumps on Canada Launch and YourBio Deal: Latest News, Forecasts and Analysis for December 4, 2025

Hims & Hers (HIMS) Stock Jumps on Canada Launch and YourBio Deal: Latest News, Forecasts and Analysis for December 4, 2025

Hims & Hers shares jumped about 8% Thursday to $40.19 after announcing a Canada launch, backed by its Livewell acquisition. The company also agreed to buy YourBio Health and recently launched a diagnostics platform with Quest Diagnostics. Market cap stands near $12.8 billion. Short interest remains high, with 67.6 million shares sold short, or about 36% of the float.
4 December 2025
···
Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

HIMS Stock Today (November 18, 2025): Buyback, GLP‑1 Price War and What It Means for Hims & Hers Investors

Hims & Hers shares closed Monday at $35.58, down 3.79%, and traded around $35.00 pre-market Tuesday after announcing a new $250 million share repurchase program. The company faces pressure from a recent sell-off and rising competition in the weight-loss drug market. Shares remain up about 70% over the past year but have dropped 29% in the last month.
18 November 2025
·
Hims & Hers Health (HIMS) Stock Falls as New ‘Labs’ Platform With Quest Diagnostics Launches – November 14, 2025 Update

Hims & Hers Health (HIMS) Stock Falls as New ‘Labs’ Platform With Quest Diagnostics Launches – November 14, 2025 Update

Hims & Hers Health shares fell about 7–8% to $36.05 Friday after launching its new Labs diagnostic platform with Quest Diagnostics. The company’s market cap stands near $8.2 billion. Labs offers nationwide blood testing and health monitoring through annual subscriptions. The stock remains up roughly 43% year-to-date but trades well below its 52-week high.
14 November 2025
··
Palantir’s Shocking Reinvention: From Secretive Spy Tech to $400B Cult Lifestyle Brand

Palantir’s ‘Otherworldly’ Earnings & Wegovy Deal Buzz Spark After-Hours Stock Fireworks

Palantir shares rose after Q3 results beat estimates and the company raised its outlook for a third straight quarter, citing surging AI platform demand. Hims & Hers stock jumped 7% post-market as it entered talks to offer Novo Nordisk’s Wegovy, despite mixed earnings. Sarepta plunged over 20% after a key Duchenne drug trial failed its main goal. Sanmina soared 18% on a strong earnings beat and guidance far above Wall Street forecasts.
4 November 2025
·······
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers said Oct. 29 it will offer clinician-supervised GLP-1 “microdose” plans using compounded semaglutide for metabolic health, priced at $1,200 for six months. The drugs, not FDA-approved, target patients with conditions like sleep apnea or high blood pressure. Medical experts warn safety data is limited and compounded versions carry risks. HIMS stock rose 2–3% after the announcement.
3 November 2025
···
Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Hims & Hers Health launched a menopause and perimenopause care program on its Hers platform Oct. 15, triggering a one-day stock surge of up to 16%. Shares quickly reversed, falling 11% to around $52–53 by Oct. 17. The company aims for $1 billion annual revenue in women’s health by 2026. Analysts remain divided, citing high valuation and volatile trading despite rapid revenue growth.
17 October 2025
·
Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Hims & Hers shares jumped 16% on Oct. 15 after launching a menopause care program, trading near $62.80 on Oct. 16, up 7% for the day. The stock has more than doubled in 2025, far outpacing rivals like Teladoc. Regulatory scrutiny from the FDA and FTC triggered brief sell-offs in September. Analyst sentiment remains cautious, with most price targets in the high $30s despite recent gains.
16 October 2025
··
Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

Hims & Hers Stock Soars on New Menopause Care Expansion – What Comes Next?

Hims & Hers shares surged nearly 13% on Oct. 15 after launching a menopause/perimenopause program on its Hers telehealth platform. The stock traded around $61 by mid-day with 29 million shares exchanged. The company now serves 2.4 million subscribers and reported Q2 revenue of $545 million, up 73% year-over-year. Analysts remain cautious, with most rating the stock Hold or Sell.
15 October 2025
·
Digital Health & Telemedicine Industry Update (June–July 2025)

Digital Health & Telemedicine Industry Update (June–July 2025)

DispatchHealth and Medically Home merged in June 2025, creating one of the largest high-acuity hospital-at-home providers under the DispatchHealth name. Novo Nordisk ended its Wegovy deal with Hims & Hers Health in late June over compounded drug concerns, causing Hims & Hers shares to drop 30%. Teladoc Health shifted strategy after acquiring Catapult Health and UpLift earlier in the year.
3 July 2025
····
1 2

Stock Market Today

  • Analysis Suggests SpaceX IPO May Be Overvalued
    June 8, 2026, 6:56 PM EDT. Despite optimistic projections, SpaceX's initial public offering (IPO) could be overvalued. Evaluations indicate that only the most ambitious 'Moonshot' scenario nearly matches the proposed IPO price, raising concerns about high market expectations. Investors should weigh potential risks given the optimistic forecasts underpinning the valuation.

Latest articles

T1 Energy Shares Dip After KORE Power Files New Update

T1 Energy Shares Dip After KORE Power Files New Update

9 June 2026
T1 Energy shares slid 3.2% to $9.13 after a new SEC filing revealed up to $24.7 million in stock-linked payments for its $32 million KORE Power acquisition, spotlighting dilution risks as the company expands into battery storage and data-center power; the deal’s structure and timing come as T1 seeks growth funding and investors weigh near-term costs against future EBITDA targets.
OpenAI IPO filing puts AI rally at center stage for Wall Street

OpenAI IPO filing puts AI rally at center stage for Wall Street

9 June 2026
OpenAI has confidentially filed for a possible IPO, but investors won’t see key financials—including revenue quality, cash burn, and compute costs—until the S-1 goes public; with $2 billion monthly revenue and a recent $852 billion valuation, the filing signals a pivotal shift as AI giants race for public capital amid rising infrastructure costs and growing competition from Anthropic.
Wall Street Volatility Index Jumps as Chip Stocks Swing

Wall Street Volatility Index Jumps as Chip Stocks Swing

9 June 2026
The VIX plunged 12% to 18.92 as chip stocks rebounded sharply, with the Philadelphia Semiconductor Index jumping 5.6% and Intel soaring 11.2% after a major Google order, clawing back part of Friday’s $1.3 trillion rout; investors remain cautious ahead of key inflation data, interest rate decisions, and Middle East risks.
UBS Puts $850 Target on Cummins as AI Data Center Wave Fuels Shares

UBS Puts $850 Target on Cummins as AI Data Center Wave Fuels Shares

9 June 2026
UBS upgraded Cummins to Buy and hiked its price target to $850 from $565, citing surging data-center backup power demand and a stronger North American truck cycle; Cummins shares jumped 3.3% to $672.68 as UBS projected 2028 EPS of $41.25, topping consensus, and flagged double-digit Power business growth and raised long-term targets as key drivers.
Go toTop